Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial.
Ciardiello D, Boscolo Bielo L, Napolitano S, Martinelli E, Troiani T, Nicastro A, Latiano TP, Parente P, Maiello E, Avallone A, Normanno N, Pisconti S, Nisi C, Bordonaro R, Russo AE, Tamburini E, Toma I, Lotesoriere C, Vallarelli S, Zampino MG, Fazio N, Curigliano G, De Vita F, Ciardiello F, Martini G; CAPRI-2 GOIM study group.
Ciardiello D, et al. Among authors: parente p.
Ann Oncol. 2024 Aug 29:S0923-7534(24)03914-0. doi: 10.1016/j.annonc.2024.08.2334. Online ahead of print.
Ann Oncol. 2024.
PMID: 39214459